Tom Chittenden

Tom joined Mythic Therapeutics in February 2020 as Head of Biology, bringing with him more than 20 years of industry experience in the discovery and preclinical evaluation of antibody-drug conjugates (ADCs) and other novel antibody-based therapies for cancer. Prior to joining Mythic, Tom led the discovery research and pipeline R&D groups at ImmunoGen, Inc., contributing to the discovery and development of multiple clinical-stage ADC candidates across a broad range of solid tumor and heme malignancies.

Earlier, Tom was the director of research at ImmunoGen’s subsidiary, Apoptosis Technology, Inc., where he focused on oncology target discovery and validation and developed new strategies to modulate intrinsic cell death pathways for cancer therapy.

Tom received his Ph.D. in molecular biology from Princeton University and completed a postdoctoral research fellowship studying the retinoblastoma tumor suppressor at Dana Farber Cancer Institute.